ImmunoGen and Sanofi Amend License Agreements
Amendments Grant Sanofi Exclusive, Fully-Paid Licenses to Selected Development Compounds
ImmunoGen to Receive
Under the terms of the amended 2003 collaboration and license agreement,
ImmunoGen has granted Sanofi a fully-paid, exclusive license to develop,
manufacture, and commercialize the following experimental compounds in
development: isatuximab (
As consideration for these amendments, ImmunoGen will receive a
"Amending these agreements allows us to continue to focus on the
development of our lead program, mirvetuximab soravtansine, while
advancing our earlier-stage portfolio and further strengthening
ImmunoGen's cash position," stated
About ImmunoGen
ImmunoGen is a clinical-stage biotechnology
company that develops targeted cancer therapeutics using its proprietary
ADC technology. ImmunoGen's lead product candidate, mirvetuximab
soravtansine, is in a Phase 3 trial for FRα-positive platinum-resistant
ovarian cancer, and is in Phase 1b/2 testing in combination regimens for
earlier-stage disease. ImmunoGen's ADC technology is used in Roche's
marketed product, Kadcyla®, in three other clinical-stage
ImmunoGen product candidates, and in programs in development by partners
Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. More
information about the Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.
This press release includes forward-looking statements. For these
statements, ImmunoGen claims the protection of the safe harbor for
forward-looking statements provided by the Private Securities Litigation
Reform Act of 1995. It should be noted that there are risks and
uncertainties related to the development of novel anticancer products,
including mirvetuximab soravtansine, and risks related to clinical
studies, their timing and results. A review of these risks can be found
in ImmunoGen's transition report on Form 10-K for the six-month
transition period ended
View source version on businesswire.com: http://www.businesswire.com/news/home/20170530005254/en/
Thrust IR
monique@thrustir.com
or
FTI
Consulting, Inc.
Robert Stanislaro, 212-850-5657
robert.stanislaro@fticonsulting.com
Source: ImmunoGen
News Provided by Acquire Media